Identification of SARS-CoV-2 Nucleocapsid and Spike T-Cell Epitopes for Assessing T-Cell Immunity

Jan 14, 2021Journal of virology

Identifying SARS-CoV-2 Nucleocapsid and Spike Protein Regions to Measure T-Cell Immunity

AI simplified

Abstract

A total of 57 immunogenic T-cell epitopes from SARS-CoV-2 were identified, which could help assess immunity and vaccine efficacy.

  • The identified epitopes are conserved across different global variants of SARS-CoV-2.
  • They exhibit binding potential to a range of HLA alleles, covering 80 to 100% of the global population.
  • Out of these, 18 epitopes show limited similarity to seasonal human coronaviruses, making them suitable for specific T-cell immunity assays.
  • Two peptides from the nucleocapsid protein triggered strong immune responses in CD8 T cells from recovered COVID-19 patients.
  • These findings may support the development of effective tools to measure cellular immune responses to SARS-CoV-2 infection and vaccines.

AI simplified

Full Text

We can’t show the full text here under this license. Use the link below to read it at the source.

what lands in your inbox each week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free